Genprex’s Promising Clinical Trials and Leadership Drive Buy Rating

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Genprex (GNPX – Research Report), retaining the price target of $10.00.

Yi Chen has given his Buy rating due to a combination of factors that underscore Genprex’s potential in the biopharmaceutical sector, particularly in the treatment of small cell lung cancer. Central to his assessment is the commencement of patient dosing in the Acclaim-3 trial, which examines the efficacy of Reqorsa in combination with Tecentriq. This treatment addresses a significant unmet medical need, as the majority of small cell lung cancers exhibit reduced TUSC2 protein expression, and Reqorsa aims to re-express this protein, potentially enhancing clinical outcomes. Additionally, the drug has already received Orphan Drug and Fast Track designations, which could expedite its development and review process. The anticipation of progressing from Phase 1 to Phase 2 trials by the second half of 2024 further solidifies the company’s forward momentum.
Furthermore, Yi Chen’s optimism is bolstered by Genprex’s broader clinical pipeline, with Reqorsa being evaluated in three distinct clinical programs targeting late-stage non-small cell lung cancer. Each of these trials is expected to reach crucial milestones by the end of 2024, which could be pivotal in demonstrating the drug’s effectiveness and versatility. The recent appointment of Ryan Confer as President, CEO, and Chairman of the Board also provides strategic continuity following the untimely passing of the company’s co-founder, ensuring steady leadership at a critical juncture in the company’s development. All these elements combine to present a compelling case for Genprex’s stock holding a Buy rating, with a promising outlook for the near future.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Genprex (GNPX) Company Description:

Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.